Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;38:105-109

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riggleman, A.
Right arrow Articles by Baylis, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riggleman, A.
Right arrow Articles by Baylis, C.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Hypertension - basic studies
Right arrow Other Vascular biology

(Hypertension. 2001;38:105.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Endothelin Mediates Some of the Renal Actions of Acutely Administered Angiotensin II

Amy Riggleman; Jeff Harvey; Chris Baylis

From the Department of Physiology (J.H., C.B.) and Department of Human Performance and Applied Exercise Science (A.R.), Division of Exercise Physiology, Department of Medicine, West Virginia University, Morgantown.

Correspondence to Chris Baylis, PhD, Department of Physiology, West Virginia University, POB 9229, Morgantown, WV 26506-9229. E-mail cbaylis{at}wvu.edu

Abstract— Recent studies suggest that endogenous endothelin mediates much of the vasoconstrictor activity and vascular fibrotic damage caused by chronic administration of angiotensin II. The present study uses the mixed endothelin-A and endothelin-B receptor antagonist bosentan and the endothelin-A-selective blocker BQ-123 to study the contribution of endogenous endothelin to the pressor and renal action of acutely administered angiotensin II in conscious, chronically catheterized rats. Exposure to angiotensin II at 0.48 pmol 0.5 ng/100 g body weight per min IV (low dose) and 1.91 pmol 2.0 ng/100 g body weight per min IV (high dose) raised mean arterial blood pressure (18±4 mm Hg, P<0.01, and 39±4 mm Hg, P<0.005, respectively) while also increasing renal vascular resistance (4.3±1 mm Hg/mL per min, P<0.001, and 10±1 mm Hg/mL per min, P<0.001, respectively). In the presence of bosentan, pressor and renal vasoconstrictor responses to low-dose angiotensin II were blunted (P<0.02 and P<0.01, respectively), and the results with BQ-123 were similar. In contrast, these parameters were unaffected during high-dose angiotensin II infusion+bosentan, although BQ-123 did selectively reduce the rise in renal vascular resistance, possibly via an endothelin B-mediated nitric oxide effect. In contrast, high-dose angiotensin II caused natriuretic and diuretic effects that were completely prevented by bosentan. These results show that endothelin (via endothelin A) contributes to the pressor and renal vasoconstrictor actions of acutely administered low-dose angiotensin II. Furthermore, our data suggest that the previously described angiotensin II-induced natriuresis and diuresis observed with a high pressor dose of angiotensin II is mediated by endothelin.


Key Words: vascular resistance • glomerular filtration rate • natriuresis • rats • angiotensin II




This article has been cited by other articles:


Home page
Exp PhysiolHome page
P. Castro-Chaves, R. Fontes-Carvalho, M. Pintalhao, P. Pimentel-Nunes, and A. F. Leite-Moreira
Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart
Exp Physiol, June 1, 2009; 94(6): 665 - 674.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. Ponnuchamy and R. A. Khalil
Cellular mediators of renal vascular dysfunction in hypertension
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1001 - R1018.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
U. C. Kopp, M. Z. Cicha, and L. A. Smith
Differential effects of endothelin on activation of renal mechanosensory nerves: stimulatory in high-sodium diet and inhibitory in low-sodium diet
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1545 - R1556.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
L. J Pearson, C. Rait, M G. Nicholls, T. G Yandle, and J. J Evans
Regulation of adrenomedullin release from human endothelial cells by sex steroids and angiotensin-II.
J. Endocrinol., October 1, 2006; 191(1): 171 - 177.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. M. Pollock
Endothelin, Angiotensin, and Oxidative Stress in Hypertension
Hypertension, April 1, 2005; 45(4): 477 - 480.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. Goddard, C. Eckhart, N. R. Johnston, A. D. Cumming, A. J. Rankin, and D. J. Webb
Endothelin A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition Are Synergistic via an Endothelin B Receptor-Mediated and Nitric Oxide-Dependent Mechanism
J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2601 - 2610.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Montanari, A. Biggi, N. Carra, M. Ziliotti, E. Fasoli, L. Musiari, P. Perinotto, and A. Novarini
Endothelin-A Receptors Mediate Renal Hemodynamic Effects of Exogenous Angiotensin II in Humans
Hypertension, October 1, 2003; 42(4): 825 - 830.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Montanari, N. Carra, P. Perinotto, V. Iori, E. Fasoli, A. Biggi, and A. Novarini
Renal Hemodynamic Control by Endothelin and Nitric Oxide Under Angiotensin II Blockade in Man
Hypertension, February 1, 2002; 39(2): 715 - 720.
[Abstract] [Full Text] [PDF]